[Aminoglutethimide-induced dyslipidemia. Experimental study].
Aminoglutethimide (AG) is a drug that inhibits steroid synthesis; it is used in advanced breast cancer. After the observation of abnormalities in lipid metabolism in patients, we realized an experimental study to try to look for a pathogenetic hypothesis. Three groups of rats received respectively AG, Hydrocortisone (HC) or both (AG + HC) and were compared to controls. Animals treated with AG (with or without HC) had a greater liver content of triglycerides, cholesterol and phospholipids than controls. Cholesterol plasma level was higher in animals treated with AG + HC. The bile flow was higher in rats receiving AG and AG + HC whereas biliary salt concentrations were lower. These variations could be the consequence of both an enzymatic induction and an inhibition of some cytochrome P450 dependent hydroxylases.
D000616:Aminoglutethimide / Q000008:administration & dosage / Q000009:adverse effects*; D000818:Animals; D001646:Bile / Q000187:drug effects / Q000502:physiology; D001647:Bile Acids and Salts / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D006854:Hydrocortisone / Q000008:administration & dosage / Q000009:adverse effects; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D014280:Triglycerides / Q000097:blood
D001647:Bile Acids and Salts; D008055:Lipids; D014280:Triglycerides; D000616:Aminoglutethimide; D002784:Cholesterol; D006854:Hydrocortisone
Dyslipémie induite par l'aminoglutéthimide (AG). Etude expérimentale.